(NASDAQ: REPL) Replimune Group's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Replimune Group's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast REPL's revenue for 2025 to be $18,416,336, with the lowest REPL revenue forecast at $18,416,336, and the highest REPL revenue forecast at $18,416,336. On average, 4 Wall Street analysts forecast REPL's revenue for 2026 to be $2,126,595,683, with the lowest REPL revenue forecast at $993,868,255, and the highest REPL revenue forecast at $3,703,525,129.
In 2027, REPL is forecast to generate $7,679,980,355 in revenue, with the lowest revenue forecast at $5,567,872,190 and the highest revenue forecast at $10,639,117,192.